In the overall patient population, 1215 (31.0%) had HR-positive/ERBB2-negative cancer, 310 (7.9%) had ERBB2-positive/HR-positive cancer, 200 (5.1%) had ERBB2-positive/HR-negative cancer, 258 (6.6%) had TNBC, and the remaining 1933 patients (49.4%) had an unknown breast cancer subtype. The gene discussed is ERBB2; the disease is breast carcinoma.